文献速递复苏、休克与脓毒症心脑血管急症

血管加压素、类固醇与肾上腺素联合方案在心脏骤停中的比较效果:临床试验的网络Meta分析

Comparative effectiveness of vasopressin, steroids, and epinephrine-based regimens in cardiac arrest: A network Meta-analysis of clinical trials.
PubMed 文献 · Am J Emerg Med · 2025-09-23
一句话结论网络Meta分析(36项RCT、21768例)显示,肾上腺素联合类固醇双联治疗与血管加压素联合类固醇及肾上腺素三联治疗(VSE)改善心脏骤停复苏结局的概率最高,排序分析一致支持VSE优于单药治疗。

该网络Meta分析纳入PubMed、Scopus、ISI Web of Science、Cochrane Central Register of Controlled Trials、Google Scholar等数据库中的36项RCT、共21768例心脏骤停患者,比较单药、双药及三联(VSE)复苏药物方案。主要结局为自主循环恢复、存活至入院、24小时存活及存活至出院,神经功能结局因测量工具异质性未行定量合成。结果显示,三联治疗(VSE)与肾上腺素联合类固醇双联治疗改善所有主要生存结局的概率最高,排序分析一致支持VSE优于单药治疗。作者认为这些发现可为未来指南与临床决策提供参考。

要点

  • 共纳入36项RCT、21768例心脏骤停患者,比较单药、双药与VSE三联方案的复苏效果。
  • 三联治疗(VSE)与肾上腺素联合类固醇双联治疗改善所有主要生存结局的概率最高。
  • 排序分析一致支持VSE三联治疗优于单药治疗改善心脏骤停患者的临床结局。
  • 主要结局包括自主循环恢复、存活至入院、24小时存活及存活至出院;神经功能结局因测量工具异质性未行定量合成。
  • 作者认为该网络Meta分析结果为肾上腺素联合类固醇双联及VSE三联治疗在心脏骤停中的优势提供了比较证据,可能为未来指南与临床决策提供参考。

适用人群与场景

  • 心脏骤停(CA)患者,纳入评估类固醇、肾上腺素与血管加压素使用的随机临床试验人群。

研究设计与关键结果

  • 研究类型为网络Meta分析,共纳入36项随机临床试验、21768例患者;检索PubMed、Scopus、ISI Web of Science、Cochrane Central Register of Controlled Trials、Google Scholar等数据库,初检3453项研究。
  • 干预按心肺复苏期间用药分为单药治疗、双药治疗或三联治疗(VSE,即血管加压素+类固醇+肾上腺素)。
  • 涉及附加药物(如利多卡因)的试验仅提取与肾上腺素/血管加压素类干预相关的数据进行分析。
  • 主要结局为自主循环恢复(ROSC)、存活至入院、24小时存活及存活至出院;神经功能结局在报告一致时评估,但因测量工具异质性未行定量合成。
  • 三联治疗(VSE)与肾上腺素联合类固醇双联治疗改善所有主要生存结局的概率最高。
  • 排序分析一致支持VSE三联治疗优于单药治疗改善心脏骤停患者的临床结局。

证据类型、等级与局限

  • 证据类型为网络Meta分析,纳入36项随机临床试验(RCT),共21768例患者。
  • PROSPERO注册号:CRD42022296508。
  • 神经功能结局因测量工具异质性未能进行定量合成。

对床旁实践的改变

  • 作者认为,该网络Meta分析提供的比较证据支持肾上腺素联合类固醇双联治疗与VSE三联治疗在改善心脏骤停复苏结局方面的优势;这些发现可能为未来指南与临床决策提供参考。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite extensive efforts to improve survival in cardiac arrest (CA), the optimal pharmacologic strategy during resuscitation remains uncertain. While prior meta-analyses have explored individual drug classes, the relative effectiveness of combined regimens remains inadequately defined. This network meta-analysis (NMA) aims to evaluate and compare the efficacy of triple therapy with vasopressin (VP), steroids, and epinephrine (EP) in CA patients.

METHODS: A comprehensive electronic search was conducted in PubMed, Scopus, ISI Web of Science, the Cochrane Central Register of Controlled Trials, Google Scholar, and other bibliographic databases. Randomized clinical trials (RCTs) evaluating the use of steroids, epinephrine, and vasopressin in CA patients were included. In trials that involved additional agents (e.g., lidocaine), only the data pertaining to epinephrine/vasopressor-based interventions were extracted and synthesized to ensure comparability with the study scope. Out of 3453 identified studies, 36 RCTs involving 21,768 patients were included. Interventions during cardiopulmonary resuscitation were categorized as monotherapy, double therapy, or triple therapy (VSE). Primary outcomes included return of spontaneous circulation (ROSC), survival to hospital admission, 24-h survival, and survival to hospital discharge. Neurological outcomes were also evaluated to determine functional recovery, when consistently reported, although heterogeneity of measurement tools precluded quantitative synthesis.

RESULTS: Triple therapy (VSE) and the combination of epinephrine plus steroids demonstrated the highest probability of improving all major survival outcomes. Ranking analysis consistently favored VSE over monotherapies to improve clinical outcomes of CA patients.

CONCLUSION: This NMA provides comparative evidence supporting the superiority of epinephrine-steroid double therapy and VSE triple therapy in improving resuscitation outcomes in cardiac arrest. These findings may inform future guidelines and clinical decision-making.

PROSPERO REGISTRATION: CRD42022296508.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Saghafi F, Dehghani MH, Erami S, et al. Comparative effectiveness of vasopressin, steroids, and epinephrine-based regimens in cardiac arrest: A network Meta-analysis of clinical trials. Am J Emerg Med. 2025. PMID: 41033062. doi:10.1016/j.ajem.2025.09.040

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。